James Joseph Faysal Ii, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 826 W King St, Owosso, MI 48867 Phone: 989-729-4977 Fax: 989-729-4062 |
News Archive
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that it has received notification that the U.S. Department of Justice and Federal Trade Commission granted early termination of the Hart-Scott-Rodino waiting period for its proposed merger with Medtronic, Inc.
Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.
FerroKin BioSciences today announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701.
Parents of autistic children can spend as much as $50,000 a year on therapies for their children. But a new research study from Case Western Reserve University's Mandel School of Applied Social Sciences shows promise of providing effective treatment for autism and other developmental disorders at a far lower cost.
› Verified 3 days ago